BeiGene (HKG:6160, SHA:688235) swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.
The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.
Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.
Shares slid 3% in Hong Kong during Wednesday's morning trading.
Price (HKD): $116.90, Change: $-4.9, Percent Change: -4.02%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。